Interim data from a mid-stage study of Roche's trastuzumab-DM1 (T-DM1) suggests that the experimental oncology therapeutic is more effective than older therapies in treating patients with HER2 positive metastatic breast cancer.
Reference Articles
Roche's cancer drug T-DM1 shows promise in study - (FinanzNachrichten)
Roche: breast cancer, lung cancer data "stunning" - (Forexyard)
ImmunoGen announces positive interim results in randomized clinical trial comparing trastuzumab-DM1 vs. standard first-line therapy for first-line HER2+ metastatic breast cancer - (ImmunoGen)
ImmunoGen's TDM-1 looks strong at ESMO - (TheStreet.com)
**Published in "First Word"
No comments:
Post a Comment